Kodiak Sciences (KOD) Proxy Filing summary

Executive summary

• The annual meeting will be held virtually on June 2, 2025, with voting on key proposals and opportunities for shareholder engagement via webcast.

• The company focuses on developing transformative retinal therapeutics, with three clinical programs in late-stage development and a robust technology platform.

• 2024 saw significant progress in clinical trials, manufacturing, and platform expansion, with topline data for major studies expected in 2026.

Voting matters and shareholder proposals

• Shareholders will vote on electing two directors, an advisory say-on-pay for executive compensation, and ratification of PricewaterhouseCoopers LLP as the independent auditor for 2025.

• The board recommends voting in favor of all proposals.

• Shareholders may submit proposals and director nominations for the 2026 meeting, following specific deadlines and procedures.

Board of directors and corporate governance

• The board consists of seven members, six of whom are independent, with staggered three-year terms.

• Nominees for election are Richard S. Levy, M.D. and Robert A. Profusek, J.D., both with extensive industry and governance experience.

• Board committees include audit, compensation, and nominating/governance, each with defined responsibilities and independent membership.

• The board emphasizes diversity, ethical standards, and regular self-evaluation.